A cost-effectiveness evaluation of two continuous-combined hormone therapies for the management of moderate-to-severe vasomotor symptoms

Menopause

Volumn 11, Issue 3, 2004, Pages 343-355

  Botteman, Marc F ^a   Shah, Nisha P ^a   Lian, Jean ^b   Pashos, Chris L ^a   Simon, James A ^c,d,e  

^a ABT ASSOCIATES   (United States)

^b PFIZER INC   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d Women's Health Research Center   (United States)

^e GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Costs and cost analysis; Economic; Hormone therapy; Menopause; Models; Public policy

Indexed keywords

CONJUGATED ESTROGEN; ETHINYLESTRADIOL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; DRUG DERIVATIVE; MEDROXYPROGESTERONE; NORETHISTERONE;

ADULT; ARTICLE; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE SEVERITY; DRUG INDICATION; FEMALE; HORMONAL THERAPY; HUMAN; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SHORT COURSE THERAPY; SPOTTING; VASOMOTOR DISORDER; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; ECONOMICS; ESTROGEN THERAPY; HOSPITALIZATION; HOT FLUSH; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; UNITED STATES;

COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); ETHINYL ESTRADIOL; FEMALE; HOT FLASHES; HUMANS; MEDROXYPROGESTERONE; MIDDLE AGED; MODELS, ECONOMIC; NORETHINDRONE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 4043184277     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GME.0000097742.96468.68     Document Type: Article

References (58)

1. Bardel A, Wallander MA, Svardsudd K. Hormone replacement therapy and symptom reporting in menopausal women: a population-based study of 35- to 65-year-old women in mid-Sweden. Maturitas 2002;41:7-15.
2. Baumgardner SB, Condrea H, Daane TA, et al. Replacement estrogen therapy for menopausal vasomotor hot flashes. Obstet Gynecol 1977;51:445-452.
3. Callantine MR, Martin PL, Bolding OT, Warner PO, Greaney MO, Jr. Micronized 17 beta-estradiol for oral estrogen therapy in menopausal women. Obstet Gynecol 1975;46:37-41.
4. Schiff I, Regestein Q, Tulchinsky D, Ryan KJ. Effects of estrogens on sleep and psychological state of hypogonadal women. JAMA 1979;242:2404-2405.
5. Sherwin BB, Gelfand MM. Effects of parenteral administration of estrogen and androgen on plasma hormone levels and hot flushes in the surgical menopause. Am J Obstet Gynecol 1984;148:552-557.
6. Sherwin BB, Gelfand MM. A prospective one-year study of estrogen and progestin in postmenopausal women: effects on clinical symptoms and lipoprotein lipids. Obstet Gynecol 1989;73:759-766.
7. Steingold KA, Laufer L, Chetkowski RJ, et al. Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab 1985;61:627-632.
8. Stephenson J. FDA orders estrogen safety warnings: agency offers guidance for HRT use. JAMA 2003;289:537-538.
9. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann intern Med 1995;122:9-16.
10. Cauley JA, Zmuda JM, Ensrud KE, Bauer DC, Ettinger B. Timing of estrogen replacement therapy for optimal osteoporosis prevention. J Clin Endocrinol Metab 2001;86:5700-5705.
11. Villareal DT, Binder EF, Williams DB, Schechtman KB, Yarasheski KE, Kohrt WM. Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial. JAMA 2001;286:815-820.
12. Gambacciani M, Ciaponi M, Cappagli B, Genazzani AR. Effects of low-dose continuous-combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women. Am J Obstet Gynecol 2001;185:1180-1185.
13. Hart DM, Parish E, Fletcher CD, et al. Long-term effects of continuous-combined HRT on bone turnover and lipid metabolism in postmenopausal women. Osteoporos Int 1998;8:326-332.
14. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
15. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66.
16. Writing Group for the Women's Health Initiative Investigator. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results. From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
17. Hays J, Ockene JK, Brunner RL, et al. Effects of Estrogen plus Progestin on Health-Related Quality of Life. N Engl J Med 2003;348:1839-1854.
18. Grady D. Postmenopausal hormones-therapy for symptoms only. N Engl J Med 2003348:1835-1837.
19. Jonsson B, Christiansen C, Johnell O, Hedbrandt J. Cost-effectiveness of fracture prevention in established osteoporosis. Osteoporos Int 1995;5:136-142.
20. Jonsson B, Kanis J, Dawson A, Oden A, Johnell O. Effect and offset of effect of treatments for hip fracture on health outcomes. Osteoporos Int 1999;10:193-199.
21. Kanis JA, Dawson A, Oden A, Johnell O, De Laet C, Jonsson B. Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 2001;12:356-361.
22. Tosteson AN, Weinstein MC. Cost-effectiveness of hormone replacement therapy after the menopause. Baillieres Clin Obstet Gynaecol 1991;5:943-959.
23. Tosteson AN, Rosenthal DI, Melton LJ, III, Weinstein MC. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 1990;113:594-603.
24. Weinstein MC. Estrogen use in postmenopausal women-costs, risks, and benefits. N Engl J Med 1980;303:308-316.
25. Weinstein MC, Schiff I. Cost-effectiveness of hormone replacement therapy in the menopause. Obstet Gynecol Surv 1983;38:445-455.
26. Ankjaer-Jensen A, Johnell O. Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporos Int 1996;6:265-275.
27. Visentin P, Ciravegna R, Fabris F. Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy. Maturitas 1997;26:185-192.
28. Norlund A. Prevention of osteoporosis-a cost-effectiveness analysis regarding fractures. Scand J Rheumatol Suppl 1996;103:42-45.
29. Office of Technology Assessment. Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy. Vol. I: Cost-Effectiveness Analysis. Washington, DC: US Congress; 1995.
30. Coyle D, Cranney A, Tugwell P. Economic evaluation of norhisterone acetate/ethinylestradiol (Femht) for women with menopausal symptoms. Pharmacoeconomics 2003;21:661-669.
31. Simon JA, Symons JP. Unscheduled bleeding during initiation of continuous-combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogens. Menopause 2001;8:321-327.
32. Simon JA, Liu JH, Speroff L, Shumel BS, Symons JP. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. Am J Obstet Gynecol 2003;188:92-99.
33. Blachmann G, Wild R, Pinkerton J, Schumel BS, Symons JP. Comparative effect of two continuous-combined hormone replacement therapies (CCHRTs) (femhrt and Prempro) on breakthrough bleeding during a 16-week study. Paper presented at 13th annual meeting of The North American Menopause Society; October 3-5, 2002; Chicago, IL.
34. Simon JA, Schumel BD, Symons JP. Effect of two continuous-combined hormone replacement therapies (femhrt and Prempro) on occurrence of bleeding in women < 2 years since last menstrual period. Paper presented at: 13th annual meeting of The North American Menopause Society; October 3-5, 2002; Chicago, IL.
35. Simon JA, Wysocki S, Brandman J, Axelsen K. A comparison of therapy continuation rates of different hormone replacement agents: A 9-month retrospective, longitudinal analysis of pharmacy claims among new users. Menopause 2003;10:37-44.
36. Jain JK, Abetz L, Brandman J. Patient reported bleeding episodes and their impact on quality of life (QOL) and treatment satisfaction: results of a randomized open-label comparative trial of femhrt versus Prempro. Abstract presented at: 13th annual meeting of The North American Menopause Society, Oct. 3-5, 2002; Chicago, IL.
37. Gold MR, Siegal JE, Russel LB, et al. Cost-Effectiveness in Health and Medicine. Oxford University Press, 1996.
38. Dere W, Avouac B, Boers M, et al. Recommendations for the health economics analysis to be performed with a drug to be registered in prevention or treatment of osteoporosis. Calcif Tissue Int 1998;63:93-97.
39. Speroff L, Symon JP, Khan S, Rowan J. The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femht) on the frequency and intensity of vasomotor symptoms. Menopause 2000;7:383-390.
40. Anderson RN. United States life tables 1997. National Vital Statistics Reports, 47 no. 28. Hyattsville, MD: National Center for Health Statistics. 1999.
41. 2003 National Fee Analyzer: Charge Data for Evaluating Fees Nationwide. Salt Lake City, UT: Ingenix, 2003.
42. Drug Topics Red Book. Update, vol. 22, no. 3. Montvale, NJ: Thompson PDR, Montvale. 2003.
43. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993;13:89-102.
44. Daly E, Gray A, Barlow D, McPherson K, Roche M, Vessey M. Measuring the impact of menopausal symptoms on quality of life. BMJ 1993;307:836-840.
45. Zethraeus N, Johannesson M, Henriksson P, Strand RT. The impact of hormone replacement therapy on quality of life and willingness to pay. Br J Obstet Gynaecol 1997;104:1191-1195.
46. Tosteson AN, Gabriel SE, Kneeland TS, et al. Has the impact of hormone replacement therapy on health-related quality of life been undervalued? J Womens Health Gend Based Med 2000;9:119-130.
47. Naglie G, Krahn MD, Naimark D, Redelmeier DA, Detsky AS. Primer on medical decision analysis: Part 3-Estimating probabilities and utilities. Med Decis Making 1997;17:136-141.
48. Feeny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status classification systems. Health Utilities Index. Pharmacoeconomics 1995;7:490-502.
49. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985;5:157-177.
50. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000;20:332-342.
51. Koster A. Hormone replacement therapy: use patterns in 51-year-old Danish women. Maturitas 1990;12:345-356.
52. Rabin DS, Cipparrone N, Linn ES, Moen M. Why menopausal women do not want to take hormone replacement therapy. Menopause 1999;6:61-67.
53. Booher DL. Estrogen supplements in menopause. Cleve Clin J Med 1990;57:154-160.
54. Kronenberg F. Hot flashes: epidemiology and physiology. Ann NY Acad Sci 1990;592:52-86.
55. Strand RT, Busschbach JJ, Caffa M, Meuleman EJ, Rutten FF. Cost-utility analysis of sildenafil compared with papaverine-phentolamine injections. BMJ 2000;320:1-6.
56. Evans KW, Boan JA, Evans JL, Shuaib A. Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine. Pharmacoeconomics 1997;12:565-577.
57. Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 1998;92:982-988.
58. Ryan PJ, Harrison R, Blake GM, Fogelman I. Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis. Br J Obstet Gynaecol 1992;99:325-328.